Jazz Pharmaceuticals's CBD Trial Misses Primary Endpoint

By MarketWatch | Aug 22, 2024 at 05:03 PM EST

Jazz Pharmaceuticals's trial of CBD for seizures in Japanese pediatric patients with certain diseases did not meet its primary goal. The company plans to collect more data and discuss a new drug application with Japanese regulatory authorities.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.